Leaning Objectives
Upon completion of this activity, you should be able to:
- Define the hemostasis and thrombosis
- Compare and contrast the mechanisms of action of direct oral anticoagulants (DOACs) and investigational Factor XI inhibitors.
- Explain DOACs and Factor XI inhibitors’ implications for thromboembolic risk and bleeding profile.
Faculty
Geoffrey D. Barnes, MD, MSc, FACC
University of Michigan
Disclosures
Consultant Fees/Honoraria: Anthos, AstraZeneca Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Boston Scientific, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc, Pfizer Inc, Sanofi-Aventis
Research/Research Grants: Blue Cross Blue Shield of Michigan, Boston Scientific
Target Audience
The target audience for this education includes cardiologists, cardiovascular nurses, nurse practitioners specializing in cardiology, physician assistants working in cardiology.
Important Dates
Date of Release: May 15, 2026
Term of Approval/Date of Expiration: May 15, 2027
Acknowledgement
Educational grant support provided by Bristol Myers Squibb and Janssen Pharmaceuticals, Inc., Alliance.